RRC ID 58678
著者 Chen YH, Lu HI, Lo CM, Hsiao CC, Li SH.
タイトル NOX4 overexpression is a poor prognostic factor in patients undergoing curative esophagectomy for esophageal squamous cell carcinoma.
ジャーナル Surgery
Abstract BACKGROUND:Nox4 has been associated with tumor progression in various types of malignancies. This study aimed to evaluate the importance of the expression of Nox4 in patients undergoing curative esophagectomy for esophageal squamous cell carcinoma.
METHODS:We reviewed retrospectively 121 patients with esophageal squamous cell carcinoma who had undergone a curative esophagectomy, including 67 patients with overexpression and 54 patients with low expression of Nox4 as evaluated by immunohistochemical analysis. In addition, 2 esophageal squamous cell carcinoma cell lines, TE11 and KYSE270, were treated with the Nox4 inhibitor GKT-137831 to explore the expression of Nox4, cell proliferative activity, and selected downstream pathways in these esophageal squamous cell carcinoma cell lines by Western blot analysis.
RESULTS:Univariate analysis showed that T1-2 status, absence of nodal metastasis, and low Nox4 expression were associated with greater disease-free survival (P = .001) and overall survival (P < .001), and Nox4 overexpression was an independent prognostic factor of worse disease-free survival and overall survival (P = .013 and P = .007, respectively). The esophageal squamous cell carcinoma cell lines treated with the Nox4 inhibitor GKT-137831 showed decreased cell proliferation in a dose-dependent manner (P < .01). Western blot analysis demonstrated that expression of AKT, phosphorylated AKT, mammalian target of rapamycin, and phosphorylated mammalian target of rapamycin were less in esophageal squamous cell carcinoma cells treated with the Nox4 inhibitor (P < .01).
CONCLUSION:This study suggests that Nox4 overexpression is a poor prognostic factor for patients with esophageal squamous cell carcinoma undergoing curative esophagectomy.
巻・号 167(3)
ページ 620-627
公開日 2020-3-1
DOI 10.1016/j.surg.2019.11.017
PII S0039-6060(19)30773-1
PMID 31889545
MeSH Adult Aged Aged, 80 and over Biomarkers, Tumor / metabolism* Cell Line, Tumor Cell Proliferation / drug effects Disease-Free Survival Esophageal Neoplasms / mortality* Esophageal Neoplasms / pathology Esophageal Neoplasms / surgery Esophageal Squamous Cell Carcinoma / mortality* Esophageal Squamous Cell Carcinoma / pathology Esophageal Squamous Cell Carcinoma / surgery Esophagectomy* Esophagus / pathology Esophagus / surgery Female Follow-Up Studies Humans Kaplan-Meier Estimate Male Middle Aged NADPH Oxidase 4 / antagonists & inhibitors NADPH Oxidase 4 / metabolism* Neoplasm Staging Prognosis Pyrazoles / pharmacology Pyrazolones Pyridines / pharmacology Pyridones Retrospective Studies
IF 3.356
引用数 0
リソース情報
ヒト・動物細胞 TE-11(RCB2100)